Table 3.
Univariate analysis for EFS and OS among MLL-r positive ALL patients
| Variables | EFS | OS | ||
|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Gender | ||||
| Male | Ref. | Ref. | ||
| Female | 5.0 (1.5, 17.5) | 0.011 | 3.8 (1.2, 12.5) | 0.025 |
| Age group | ||||
| < 1 | Ref. | Ref. | ||
| ≥ 1, < 10 | 0.3 (0.1, 1.1) | 0.072 | 0.3 (0.1, 1.3) | 0.101 |
| ≥ 10 | 0.1 (0.0, 0.8) | 0.028 | 0.2 (0.0, 2.2) | 0.183 |
| Chemotherapy protocol | ||||
| GD-ALL-2008 Protocol | Ref. | Ref. | ||
| SCCLG-ALL-2016 Protocol | 1.2 (0.4, 3.1) | 0.745 | 1.4 (0.1, 17.6) | 0.771 |
| WBC group | ||||
| < 50 × 109/L | Ref. | Ref. | ||
| ≥ 50 × 109/L | 2.7 (1.1, 7.1) | 0.039 | 16.9 (1.5, 185.3) | 0.021 |
| Hb group | ||||
| < 110 g/L | Ref. | Ref. | ||
| ≥ 110 g/L | 0.8 (0.2, 3.8) | 0.797 | 1.5 (0.6, 4.0) | 0.425 |
| PLT group | ||||
| < 100 × 109/L | Ref. | Ref. | ||
| ≥ 100 × 109/L | 0.2 (0.0, 1.9) | 0.175 | 0.6 (0.2, 1.5) | 0.260 |
| Risk group | ||||
| SR | Ref. | Ref. | ||
| IR | 1.6 (0.3, 7.5) | 0.576 | 4.9 (0.5, 47.5) | 0.170 |
| HR | 1.8 (0.5, 6.8) | 0.399 | 1.7 (0.1, 26.8) | 0.717 |
| Immunophenotype | ||||
| B -cell | Ref. | Ref. | ||
| T-cell | 6.7 (1.5, 29.6) | 0.012 | 2.8 (1.1, 7.1) | 0.031 |
| MLL partner gene | ||||
| MLL-PTD | Ref. | Ref. | ||
| MLL-AF4 | 4.8 (1.4, 17.1) | 0.015 | 6.4 (1.6, 24.8) | 0.007 |
| MLL-ENL | 1.2 (0.2, 7.0) | 0.872 | 1.7 (0.1, 26.8) | 0.717 |
| Others | 0.9 (0.1, 5.3) | 0.882 | 1.2 (0.1, 19.9) | 0.883 |
| Prednisone Response | ||||
| PGR | Ref. | Ref. | ||
| P PR | 1.8 (0.5, 6.7) | 0.399 | 2.0 (0.6, 7.4) | 0.285 |
| D15 BM | ||||
| M1 | Ref. | Ref. | ||
| M2/M3 | 1.4 (0.4, 4.7) | 0.633 | 2.0 (0.6, 6.6) | 0.243 |
| D33 BM | ||||
| M1 | Ref. | Ref. | ||
| M2/M3 | 1.0 (0.2, 4.2) | 0.960 | 0.5 (0.0, 9.9) | 0.683 |
| D15 MRD | ||||
| < 0.1% | Ref. | Ref. | ||
| ≥ 0.1% | 3.6 (1.1, 12.4) | 0.041 | 5.8 (1.2, 29.0) | 0.031 |
| D33 MRD | ||||
| < 0.01% | Ref. | Ref. | ||
| ≥ 0.01% | 0.5 (0.1, 3.8) | 0.498 | 2.1 (0.4, 10.1) | 0.360 |
| SCT | ||||
| No | Ref. | Ref. | ||
| Yes | 0.4(0.2, 0.9) | 0.027 | 0.1 (0.0, 0.8) | 0.027 |
Abbreviation: WBC white blood cell, Hb haemoglobin, PLT platelet, CNS L central nervous system leukemia, SR standard risk, IR intermediate risk, HR high risk, PGR prednisone good response, PPR prednisone poor response, MRD minimal residual disease evaluation, BM bone marrow, SCT stem cell transplantation